Pembrolizumab (pembro) in children and young adults with low-risk classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo): Early results from the phase 2 KEYNOTE-667 study Meeting Abstract
| Authors: | Roth, L. G.; Keller, F.; Toledo, M. M.; Castellino, S. M.; Forlenza, C. J.; Catalan, M. A.; Krystal, J.; Lamble, A.; Rao, A. V.; Morales, F. M.; Cooper, S.; Luisi, F.; Llano, O. G.; Lopez, K. A.; Mauz-Koerholz, C.; Hoppe, B.; Shen, J.; Pillai, P.; Marinello, P.; Kelly, K. M. |
| Abstract Title: | Pembrolizumab (pembro) in children and young adults with low-risk classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo): Early results from the phase 2 KEYNOTE-667 study |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 1700 |
| Language: | English |
| ACCESSION: | WOS:001159306706171 |
| DOI: | 10.1182/blood-2023-186719 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
